Mark Alles

Biopharma Celgene Corporation (NASDAQ: CELG) reported first-quarter earnings, lowered its 2018 full-year EPS guidance and raised its sales guidance for the year before the open Friday.  What Happened Total net product sales of $3.53 billion in Q1 were 20 percent higher from the same...

Shares of Celgene Corporation (NASDAQ: CELG) were trading higher by 0.43 percent at $108.11 after the company reported its second-quarter results. Celgene said it earned $1.44 per share in the second quarter on revenue of $2.74 billion. Wall Street analysts were expecting the company to earn $1.39...